Illumina develops and sells DNA sequencing instruments, consumables and related software used in genomics research and clinical applications. Its next-generation sequencing platforms are widely adopted in academic labs, biopharma and diagnostic settings for reading genetic material at scale. Recurring reagent and flow-cell sales complement instrument placements as a core part of the business model.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,041 | — | 131 | 791.1% |
| Q2 2025 | 1,059 | — | 235 | 309.8% |
| Q3 2025 | 1,084 | — | 150 | -18.7% |
| Q4 2025 | 1,159 | — | 334 | 144.9% |
| Q1 2026 | 1,091 | 4.8% | 134 | 2.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Alnylam Pharmaceuticals, Inc. (ALNY), GE HealthCare Technologies Inc. (GEHC), Biogen Inc. (BIIB), Willis Towers Watson Public Limited Company (WTW), Copart, Inc. (CPRT), Zscaler, Inc. (ZS)